Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang

publication date: May 17, 2018

WuXi Biologics will build a $240 million CDMO facility in Shijiazhuang, the capital of China's northern Hebei province. The new facility is an addition to WuXi Biologics' existing CDMO facilities in Shanghai and a $392 million biologics CDMO facility in Ireland, announced last month. WuXi said the Shijiazhuang facility, which will employ 1,000 people, will be operational in 2020. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.